Compare DexCom, Inc. (DXCM) vs Medline Inc. Class A Common Stock (MDLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Medline Inc. Class A Common Stock — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Medline Inc. Class A Common Stock trades at $35.74 (market cap $31.10B). The key difference: DexCom, Inc. and Medline Inc. Class A Common Stock are close in size by market cap, and DexCom, Inc. is trading nearer its 52-week high, Medline Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Medline Inc. Class A Common Stock for 0 Days on average.
| DXCM | MDLN | |
|---|---|---|
Market Cap | $31.81B | $31.10B |
Volume | 2,861,821 | 4,471,639 |
Sector | Health | Health |
52-Week High | $92.34 | $49.99 |
52-Week Low | $54.84 | $31.64 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.26B | $41.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Medline Inc. Class A Common Stock
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →
